Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors
Frontiers in Cellular and Infection Microbiology · 03.03.2023 · 13
DOI: 10.3389/fcimb.2023.1099063 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 03.03.2023. Verfasst von Yifan Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking Universi…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Neoplasms, Gastrointestinal Neoplasms, Colonic Neoplasms. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege, Patientensicherheit
Abstract (Originalsprache)
Introduction
The wide application of immune checkpoint inhibitors has significantly improved the survival expectation of cancer patients. While immunotherapy brings benefits to patients, it also results in a series of immune-related adverse events (irAEs). Increasing evidence suggests that the gut microbiome is critical for immunotherapy response and the development of irAEs.
Methods
In this prospective study, we recruited 95 patients with advanced/unresectable gastrointestinal cancers treated with immunotherapy and report a comprehensive analysis of the association of the gut microbiome with irAEs. Metagenome sequencing was used to analyze the differences in bacterial composition and metabolic pathways of baseline fecal samples.
Results
In summary, we identified bacterial species and metabolic pathways that might be associated with the occurrence of irAEs in gastric, esophageal, and colon cancers. Ruminococcus callidus and Bacteroides xylanisolvens were enriched in patients without severe irAEs. Several microbial metabolic pathways involved in the urea cycle, including citrulline and arginine biosynthesis, were associated with irAEs. We also found that irAEs in different cancer types and toxicity in specific organs and the endocrine system were associated with different gut microbiota profiles. These findings provide the basis for future mechanistic exploration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China.
- Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, China.
- Xbiome, Shenzhen, China.
- Department of Colorectal Surgery, China-Japan Friendship Hospital, Beijing, China.
Zitieren
APA
Zhang, Y., Cheng, S., Zou, H., Han, Z., Xie, T., Zhang, B., Dai, D., Yin, X., Liang, Y., Kou, Y., Tan, Y., Shen, L., & Peng, Z. (2023). Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors. Frontiers in Cellular and Infection Microbiology, 13. https://doi.org/10.3389/fcimb.2023.1099063
Vancouver
Zhang Y, Cheng S, Zou H, Han Z, Xie T, Zhang B, et al. Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors. Frontiers in Cellular and Infection Microbiology. 2023;13. doi:10.3389/fcimb.2023.1099063
BibTeX
@article{Zhang2023,
author = {Zhang, Yifan and Cheng, Siyuan and Zou, Hua and Han, Zihan and Xie, Tong and Zhang, Bohan and Dai, Die and Yin, Xiaochen and Liang, Yong and Kou, Yan and Tan, Yan and Shen, Lin and Peng, Zhi},
title = {Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2023},
volume = {13},
doi = {10.3389/fcimb.2023.1099063}
}
EUVIMED